Literature DB >> 7909395

T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.

M Berger1, P J Wettstein, R Korngold.   

Abstract

T cell responses to multiple minor histocompatibility antigens are governed by the complex phenomenon of immunodominance, as demonstrated clearly in the generation of CTL in the C57BL/6By (B6) anti-BALB.B strain combination. Immunodominance has also been found in lethal graft-versus-host disease (GVHD) responses directed to BALB.B minor histocompatibility antigens, after transplantation of B6 T cells and T cell-depleted bone marrow to irradiated (825 cGy) recipients of either the BALB.B or CXB recombinant inbred strains. However, previous results indicated that the hierarchy of immunodominance in GVHD differed from that predicted from the in vitro CTL studies. Lethal GVHD was observed in BALB.B, CXBE, CXBI, and CXBJ recipients, but not in CXBG and CXBK recipients, the latter 2 strains expressing immunodominant antigens for CTL generation. A major hypothesis to account for these discordant observations is that GVHD reflected the activity of CD4+, but not CD8+, T cell subsets, in contrast to only the in vitro cytolytic potential of CD8+ T cells. Therefore, the current study was undertaken to assess the GVHD potential of both T cell subsets in the B6-->BALB.B, CXBE, CXBI, and CXBJ strain combinations and to analyze the early GVHD responses in the B6-->CXBG and CXBK strains. The results indicate that lethal GVHD responses in the B6-->BALB.B combination can be mediated by either CD4+ T cells or CD4-dependent CD8+ T cells; a similar observation was made with the B6-->CXBI strain combination. Lethal GVHD in the B6-->CXBE strain combination is mediated only by CD4-dependent CD8+ T cells, whereas GVHD in the B6-->CXBJ combination involves either CD4+ T cells alone or CD4-independent CD8+ T cells. In the B6-->CXBG and CXBK recipients, which do not develop lethal GVHD, the early phases of a GVHD response was detected with involvement of both CD4+ and CD8+ T cells. These results indicate that CD8+ T cells are active at some level in all of the strain combinations tested, that CD4+ T cells do not account for the GVHD immunodominant response in the CXBE recipients, and that the failure to obtain extensive clinical disease in the CXBG and CXBK strains is not due to a lack of a graft-versus-host response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909395

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

1.  Survival and function of MiHA epitope-specific host CD8 TM cells following ablative conditioning and HCT.

Authors:  Alwi M Shatry; Derry C Roopenian; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2007-03       Impact factor: 5.742

2.  The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease.

Authors:  Shan He; Fang Xie; Yongnian Liu; Qing Tong; Kazuhiro Mochizuki; Philip E Lapinski; Ram-Shankar Mani; Pavan Reddy; Izumi Mochizuki; Arul M Chinnaiyan; Shin Mineishi; Philip D King; Yi Zhang
Journal:  Blood       Date:  2013-10-18       Impact factor: 22.113

3.  Inter-strain tissue-infiltrating T cell responses to minor histocompatibility antigens involved in graft-versus-host disease as determined by Vbeta spectratype analysis.

Authors:  Jenny Zilberberg; Danielle McElhaugh; Loise N Gichuru; Robert Korngold; Thea M Friedman
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

4.  Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD.

Authors:  Anne-Kathrin Hechinger; Benjamin A H Smith; Ryan Flynn; Kathrin Hanke; Cameron McDonald-Hyman; Patricia A Taylor; Dietmar Pfeifer; Björn Hackanson; Franziska Leonhardt; Gabriele Prinz; Heide Dierbach; Annette Schmitt-Graeff; Jiri Kovarik; Bruce R Blazar; Robert Zeiser
Journal:  Blood       Date:  2014-10-28       Impact factor: 22.113

5.  T-cell receptor V(alpha) usage by effector CD4+Vbeta11+ T cells mediating graft-versus-host disease directed to minor histocompatibility antigens.

Authors:  Christine G DiRienzo; George F Murphy; Thea M Friedman; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2007-03       Impact factor: 5.742

6.  Analysis of graft-versus-host disease (GVHD) and graft rejection using MHC class I-deficient mice.

Authors:  S Shenoy; K Desch; B Duffy; P Thorson; T Mohanakumar
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

7.  T cell-specific notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells.

Authors:  Ashley R Sandy; Jooho Chung; Tomomi Toubai; Gloria T Shan; Ivy T Tran; Ann Friedman; Timothy S Blackwell; Pavan Reddy; Philip D King; Ivan Maillard
Journal:  J Immunol       Date:  2013-05-01       Impact factor: 5.422

8.  Induction of graft-versus-host disease and in vivo T cell monitoring using an MHC-matched murine model.

Authors:  Bryan A Anthony; Gregg A Hadley
Journal:  J Vis Exp       Date:  2012-08-29       Impact factor: 1.355

Review 9.  Mouse models of graft-versus-host disease: advances and limitations.

Authors:  Mark A Schroeder; John F DiPersio
Journal:  Dis Model Mech       Date:  2011-05       Impact factor: 5.758

10.  The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.

Authors:  Marina G M Castor; Vanessa Pinho; Mauro M Teixeira
Journal:  Front Pharmacol       Date:  2012-02-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.